title: Proliferative lesions of oviduct and uterus in CD-1 mice exposed prenatally to tamoxifen.
abstract: Tamoxifen (TAM) is widely used as adjuvant breast cancer therapy after surgery and as a chemopreventive agent in women of child-bearing age. However, TAM therapy has been shown to result in an increased incidence of endometrial carcinoma in women. The present study was designed to investigate the effects of TAM (5 mg/kg and 7.5 mg/kg body wt) given i.g. to pregnant CD-1 mice (1x/day, days 12 through 18 of gestation) on their female offspring. Progressive proliferative hyperplasia of the oviduct was frequently seen in TAM-exposed offspring, reaching 100% incidence by 52 weeks in both treatment groups. These females also developed progressive proliferative uterine lesions, including moderate/severe cystic endometrial hyperplasia (34-50%) and polypoid adenomas (27-30%) between 53 and 78 weeks. Deciduomas (15%) occurred at young ages (12 and 24 weeks) while leiomyomas (14%), a malignant leiomyosarcoma, and ovarian granulosa cell tumors (14%), were found between 72 and 78 weeks. Our findings thus suggest a strong association between transplacental TAM and reproductive tract abnormalities in female CD-1 mice.
authors.affiliation: Intramural Research Support Program, SAIC Frederick, National Cancer Institute, Frederick Cancer Research and Development Center, MD 21702-1201, USA.
authors.forename: B A
authors.initials: BA
authors.lastname: Diwan
authors.forename: L M
authors.initials: LM
authors.lastname: Anderson
authors.forename: J M
authors.initials: JM
authors.lastname: Ward
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000009:adverse effects*; D004714:Endometrial Hyperplasia / Q000139:chemically induced; D004965:Estrogen Antagonists / Q000009:adverse effects*; D005187:Fallopian Tubes / Q000187:drug effects* / Q000473:pathology; D005260:Female; D006965:Hyperplasia / Q000139:chemically induced; D008297:Male; D051379:Mice; D011127:Polyps / Q000139:chemically induced; D011230:Precancerous Conditions / Q000139:chemically induced; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D013629:Tamoxifen / Q000009:adverse effects*; D014594:Uterine Neoplasms / Q000139:chemically induced; D014599:Uterus / Q000187:drug effects*
chemical_list: D016588:Anticarcinogenic Agents; D004965:Estrogen Antagonists; D013629:Tamoxifen